GLP1R and type 2 diabetes mellitus: In summary, our observations suggest that GLP-1 RAs may be associated with a reduction in the risk of mortality, MACEs, and MAKEs in patients with type 2 diabetes following severe AKI, over a median follow-up of 2.3 years.